Article thumbnail

Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients

By Gianmaria Baldin, Arturo Ciccullo, Stefano Rusconi, Amedeo Capetti, Gaetana Sterrantino, Manuela Colafigli, d&apos, Andrea Giacometti, Maria Vittoria Cossu, Alberto Borghetti, William Gennari, Cristina Mussini, Vanni Borghi and Simona Di Giambenedetto

Abstract

Results from clinical trials and observational studies suggest that lamivudine plus dolutegravir (3TC+DTG) could be an effective and tolerated option for simplification in human immunodeficiency virus (HIV)-1-positive patients

Topics: ART, Dolutegravir, HIV, Lamivudine, Simplification, Two-drug regimen
Publisher: 'Elsevier BV'
Year: 2019
DOI identifier: 10.1016/j.ijantimicag.2019.09.002
OAI identifier: oai:iris.unimore.it:11380/1195941
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://hdl.handle.net/11380/11... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.